Access to ERS Genomics’ foundational CRISPR/Cas9 patent portfolio expands our genetic engineering toolkit and strengthens our ability to speed up and optimize strain development across Dyadic’s ...
News-Medical.Net on MSN
One-time CRISPR therapy safely lowers cholesterol and triglycerides in early trial
In a 15-patient, Phase 1 one, first-in-human trial, a one-time, CRISPR-Cas9 gene-editing therapy safely reduced LDL ...
The possibility of editing our genes once seemed more like science fiction than reality. Times have changed with the development of CRISPR-Cas9, a gene-editing tool first used in 2012. Gene editing is ...
License enables Dyadic Applied BioSolutions to expand genetic engineering capabilities DUBLIN and JUPITER, Fla., Nov. 10, 2025 /PRNewswire/ -- ERS Genomics Limited ('ERS') ...
Gene-editing techniques such as CRISPR-Cas9 have many uses in the area of food and agriculture. They can combat persistent drought and disease, and improve the colour and nutritional content of food ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback